These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 24748756)
1. Pharmacophore and Virtual Screening of JAK3 inhibitors. Rajeswari M; Santhi N; Bhuvaneswari V Bioinformation; 2014; 10(3):157-63. PubMed ID: 24748756 [TBL] [Abstract][Full Text] [Related]
2. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3). Kaur M; Silakari O J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281 [TBL] [Abstract][Full Text] [Related]
3. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer. Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730 [TBL] [Abstract][Full Text] [Related]
4. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. Dymock BW; See CS Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873 [TBL] [Abstract][Full Text] [Related]
5. Putative dual inhibitors of Janus kinase 1 and 3 (JAK1/3): Pharmacophore based hierarchical virtual screening. Jasuja H; Chadha N; Singh PK; Kaur M; Bahia MS; Silakari O Comput Biol Chem; 2018 Oct; 76():109-117. PubMed ID: 29990790 [TBL] [Abstract][Full Text] [Related]
7. Identification of novel covalent JAK3 inhibitors through consensus scoring virtual screening: integration of common feature pharmacophore and covalent docking. Qiu G; Yu L; Jia L; Cai Y; Chen Y; Jin J; Xu L; Zhu J Mol Divers; 2024 Jul; ():. PubMed ID: 39009908 [TBL] [Abstract][Full Text] [Related]
8. Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach. Jasuja H; Chadha N; Kaur M; Silakari O Mol Divers; 2014 May; 18(2):253-67. PubMed ID: 24415188 [TBL] [Abstract][Full Text] [Related]
9. Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors. Zhong HA; Almahmoud S Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047004 [TBL] [Abstract][Full Text] [Related]
10. JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present). Chen C; Lu D; Sun T; Zhang T Expert Opin Ther Pat; 2022 Mar; 32(3):225-242. PubMed ID: 34949146 [TBL] [Abstract][Full Text] [Related]
11. Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors. Dai J; Yang L; Addison G Mini Rev Med Chem; 2019; 19(18):1531-1543. PubMed ID: 31288716 [TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors. Kaur M; Singh PK; Singh M; Bahadur R; Silakari O Mol Divers; 2018 Feb; 22(1):95-112. PubMed ID: 29138965 [TBL] [Abstract][Full Text] [Related]
14. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946 [TBL] [Abstract][Full Text] [Related]
15. Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy. James N; Ramanathan K Cell Biochem Biophys; 2018 Jun; 76(1-2):111-124. PubMed ID: 28477056 [TBL] [Abstract][Full Text] [Related]
16. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways. Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W Front Immunol; 2022; 13():884399. PubMed ID: 35693820 [TBL] [Abstract][Full Text] [Related]